The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Table 1

Baseline characteristics of the included studies.

First author, study acronym	Year published	Number of participants	Intervention	Prestudy OAD treatment (%)			Duration of treatments (weeks)	Baseline characteristics
				None	Monotherapy	Combination therapy		Age (years) mean (SD)	Duration of T2DM (years)	HbA1c (%)	FBG (mmol/L)	BMI
1 (Derosa)	2009	60	EXBID		60 (100)		26
1 (Derosa)		61	Glibenclamide		61 (100)		26
2 (Diamant)	2010	233	EXQW		164 (70)	69 (30)	26
2 (Diamant)		223	Insulin glargine		157 (70)	66 (30)	26
3 (Russell)	2012	248	EXQW	248 (100)			26
3 (Russell)		246	MET	246 (100)			26
		163	PIO	163 (100)			26
		163	SITA	163 (100)			26
4 (Derosa)	2013	84	EXBID		84 (100)		26
4 (Derosa)		83	Placebo		83 (100)		26
5 (Linong)	2013	338	EXBID				26
5 (Linong)		340	EXQW				26
6 (W.XU)	2015	142	EXBID	142 (100)			48
6 (W.XU)		138	Insulin	138 (100)			48
		136	PIO	136 (100)			48
7 (YIN)	2018	19	EXBID		19 (100)		16
7 (YIN)		20	Insulin		20 (100)		16
8 (Ahmann)	2018	404	Semaglutide QW				56	56.4 (20-82)	9.0 (0.4-37.1)	8.4 (6.7-11.1)		34.0 (21.0-72.8)
8 (Ahmann)		405	EXQW				56	56.7 (21-83)	9.4 (0.3-54.0)	8.3 (6.5-11.2)		33.6 (21.2-55.8)